|0.793|| +0.033 / +4.34%|
Synthetic Biologics, Inc. is a clinical stage company, which develops therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. Its products portfolio includes SYN-004 and SYN-010. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
|Jeffrey Lucero Riley||President, Chief Executive Officer & Director|
|Steven A. Shallcross||Chief Financial Officer, Secretary & Treasurer|
|Michael Kaleko||Senior Vice President-Research & Development|
|Joseph Sliman||Senior VP-Clinical & Regulatory Affairs|
|Deb Mathews||Vice President-Medical Affairs|